An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance

An Evaluation of Use of Topical Ocular Hypotensive Medication by Electronic Compliance Measures

This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.

This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.

Inclusion Criteria:

• Currently using one or two topical ocular hypotensive medications

Exclusion Criteria:

• Hypersensitivity to any component of medication